Table 1. Clinicopathological findings of primary tumours.
| Factors | Therapy for primary tumour, n (%) | P | |
|---|---|---|---|
| dCRT | Surgery | ||
| Total number | 33 | 9 | |
| Age (years), median [range] | 64 [48–81] | 58 [47–69] | 0.213 |
| Sex | 0.443 | ||
| Male | 29 (87.9) | 7 (77.8) | |
| Female | 4 (12.1) | 2 (22.2) | |
| Location of the tumour | 0.740 | ||
| Cervical | 8 (24.2) | 1 (11.1) | |
| Thoracic upper third | 5 (15.2) | 2 (22.2) | |
| Thoracic middle third | 13 (39.4) | 4 (44.5) | |
| Thoracic lower third | 7 (21.2) | 2 (22.2) | |
| Abdominal | 0 (0.0) | 0 (0.0) | |
| Histology | 1.000 | ||
| Squamous cell carcinoma | 33 (100.0) | 9 (100.0) | |
| Others | 0 (0.0) | 0 (0.0) | |
| cT category | 0.023 | ||
| 1 | 13 (39.4) | 0 (0.0) | |
| 2 | 3 (9.1) | 3 (33.3) | |
| 3 | 13 (39.4) | 4 (44.5) | |
| 4 | 4 (12.1) | 2 (22.2) | |
| cN category | 0.740 | ||
| 0 | 13 (39.4) | 3 (33.3) | |
| 1 | 17 (51.5) | 3 (33.3) | |
| 2 | 2 (6.1) | 3 (33.3) | |
| 3 | 1 (3.0) | 0 (0.0) | |
| cM category | 0.614 | ||
| 0 | 28 (84.8) | 7 (77.7) | |
| 1 (supraclavicular LN) | 5 (15.2) | 2 (22.3) | |
| cStage | 0.191 | ||
| I | 11 (33.3) | 1 (11.1) | |
| II | 4 (12.1) | 3 (33.3) | |
| III | 13 (39.4) | 3 (33.3) | |
| IV | 5 (15.2) | 2 (22.3) | |
| Recurrent or residual site | <0.001 | ||
| LN | 30 (90.9) | 3 (33.3) | |
| Cervical | 11 (33.3) | 3 (33.3) | |
| Mediastinal | 10 (30.3) | 0 (0.0) | |
| Abdominal | 9 (27.3) | 0 (0.0) | |
| Lung | 3 (9.1) | 3 (33.3) | |
| Brain | 0 (0.0) | 2 (22.3) | |
| Muscle | 0 (0.0) | 1 (11.1) | |
| Median disease-free interval (days), median [range] | 484 [162–2,283] | 640 [76–1,443] | 0.919 |
| LN | |||
| Cervical | 497 [162–2,283] | 197 [76–1,077] | 0.517 |
| Mediastinal | 553 [307–1,358] | – | |
| Abdominal | 434 [223–1,540] | – | |
| Lung | 1,087 [474–1,232] | 792 [454–1,443] | 1.000 |
| Brain | – | 387 [134–640] | – |
| Muscle | – | 747 | – |
dCRT, definitive chemoradiotherapy; LN, lymph node.